<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id><journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id><journal-title-group><journal-title>Frontiers in Neurology</journal-title></journal-title-group><issn pub-type="epub">1664-2295</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401027</article-id><article-id pub-id-type="pmc">PMC12093408</article-id><article-id pub-id-type="doi">10.3389/fneur.2025.1590950</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Twitch force in human Amyotrophic Lateral Sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Libonati</surname><given-names>Laura</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2997847/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Cambieri</surname><given-names>Chiara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/385578/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Ceccanti</surname><given-names>Marco</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Moret</surname><given-names>Federica</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1810383/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Di Giulio</surname><given-names>Matteo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Palma</surname><given-names>Eleonora</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/100508/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Inghilleri</surname><given-names>Maurizio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/117285/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Human Neurosciences, Rare Neuromuscular Diseases Center, Sapienza University of Rome, Viale Dell&#x02019;Universit&#x000e0;</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Physiology and Pharmacology, Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome Sapienza</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff3"><sup>3</sup><institution>IRCCS Neuromed</institution>, <addr-line>Pozzilli</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Christian Lunetta, IRCCS Scientific Clinical Institute Maugeri, Italy</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Minttu Marttila, University of Helsinki, Finland</p><p>Riccardo Zuccarino, NEuroMuscular Omnicentre (NEMO), Italy</p><p>Tracy L. Peters, Fujian Medical University, China</p></fn><corresp id="c001">*Correspondence: Maurizio Inghilleri, <email>maurizio.inghilleri@uniroma1.it</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1590950</elocation-id><history><date date-type="received"><day>10</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Libonati, Cambieri, Ceccanti, Moret, Di Giulio, Palma and Inghilleri.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Libonati, Cambieri, Ceccanti, Moret, Di Giulio, Palma and Inghilleri</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Introduction</title><p>This study investigated differences in muscle twitch force between slow and fast progressors of amyotrophic lateral sclerosis (ALS) to better understand disease heterogeneity and identify potential biomarkers of disease progression.</p></sec><sec id="sec2"><title>Methods</title><p>Forty-four ALS patients were classified as slow or fast progressors based on disease progression rates. Electrophysiological assessments, including compound muscle action potential (CMAP) and muscle force measurements, were conducted. Creatine kinase (CK) levels were also evaluated.</p></sec><sec id="sec3"><title>Results</title><p>Slow progressors demonstrated significantly higher muscle peak force and area under the curve (AUC) compared to fast progressors, reflecting greater muscle strength and endurance. CK levels were also elevated in slow progressors.</p></sec><sec id="sec4"><title>Discussion</title><p>Despite similar CMA<italic>p</italic> values, slow progressors retained greater muscle strength, possibly due to a reduced degeneration of fast-twitch fibers and compensatory axonal sprouting. These adaptations may preserve muscle function and elevate CK levels, suggesting better muscle integrity in slow progressors.</p></sec><sec id="sec5"><title>Conclusion</title><p>Muscle function profiles and CK levels are promising indicators of ALS progression. These findings could enhance early detection of disease progression and lead to targeted interventions to preserve muscle function. Further research is needed to validate these results and explore the underlying functional mechanisms of disease heterogeneity.</p></sec></abstract><kwd-group><kwd>amyotrophic lateral sclerosis</kwd><kwd>muscle function</kwd><kwd>electromechanical coupling</kwd><kwd>disease phenotype</kwd><kwd>disease progression</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="43"/><page-count count="7"/><word-count count="5271"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neuromuscular Disorders and Peripheral Neuropathies</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec6"><title>Highlights</title><p>
<list list-type="bullet"><list-item><p><italic>Differentiation of ALS Phenotypes</italic>: ALS slow progressors show greater muscle strength despite similar electrophysiological traits, highlighting phenotype diversity.</p></list-item><list-item><p><italic>Insight into ALS Pathogenesis</italic>: Study underlines the muscle&#x02019;s role in ALS, emphasizing the muscle function &#x00026; electromechanical coupling&#x02019;s impact on disease progression.</p></list-item><list-item><p><italic>Implications for Therapeutic Interventions</italic>: Linking muscle function to ALS progression can preserve muscle integrity, slow disease progression, and enhance patient outcomes.</p></list-item></list>
</p></sec><sec sec-type="intro" id="sec7"><title>Introduction</title><p>Amyotrophic Lateral Sclerosis (ALS) is a fatal adult-onset neurodegenerative disease characterized by progressive degeneration of motor neurons in the brain cortex, brainstem, and spinal cord, leading to muscular weakness, atrophy, respiratory failure, and death within 2&#x02013;3&#x0202f;years of symptom onset in most cases (<xref rid="ref1" ref-type="bibr">1&#x02013;4</xref>). While neuronal dysfunction marks the disease&#x02019;s initial phase, the mechanisms underlying progression remain poorly understood (<xref rid="ref5" ref-type="bibr">5</xref>). Clinically, ALS is highly heterogeneous, with variability in affected body regions, the degree of upper and lower motor neuron involvement, and associated behavioral and cognitive changes (<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>). Disease progression also varies, with patients categorized as fast or slow progressors based on the progression index (PI), calculated as the monthly decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score from symptom onset (<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>). However, the factors driving this variability&#x02014;whether intrinsic or environmental&#x02014;are not fully elucidated, and reliable biomarkers to predict disease progression remain lacking (<xref rid="ref10" ref-type="bibr">10</xref>).</p><p>Understanding factors that influence disease progression is crucial for developing targeted therapies. Recent research has highlighted the potential role of muscles in the pathophysiological process of ALS, with compensatory mechanisms, such as collateral sprouting of nerve fibers, mitigating clinical effects in the early stages of the disease (<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>). Muscle strength is determined by a combination of factors, including muscle fiber size and type, as well as neurological components like cortical excitability, neuromuscular junction integrity, electromechanical coupling, and the efficiency of the muscle contraction system (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>).</p><p>In ALS, motor neuron degeneration leads to progressive muscle atrophy and loss of force. Compound muscle action potential (CMAP), which reflects the sum of motor unit action potentials (MUAPs) generated at motor endplates, decreases as the disease advances (<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref16" ref-type="bibr">16</xref>). Additionally, late-stage ALS is marked by a reduced electromechanical coupling efficiency and variable degeneration of muscle fiber types (<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>). Despite these changes, there is limited understanding of how these factors differ between fast and slow progressors.</p><p>This study aimed to investigate electromechanical coupling efficiency in ALS by focusing on the flexor muscles of the fingers. Specifically, we compared the contractile force evoked by supramaximal stimulation of the median nerve at the elbow with the amplitude of CMAP recorded in the flexor muscles of the fingers. By analyzing differences between fast and slow progressors, we sought to gain insights into the mechanisms underlying disease heterogeneity and progression.</p></sec><sec sec-type="materials|methods" id="sec8"><title>Materials and methods</title><p>We enrolled 44 patients (22 males and 22 females) diagnosed with definite Amyotrophic Lateral Sclerosis (ALS) according to the revised El Escorial criteria (<xref rid="ref19" ref-type="bibr">19</xref>). Diagnosis was made by experienced neurologists based on clinical and electrophysiological assessments.</p><p>Bulbar onset was observed in 10 patients. All patients provided written informed consent before study enrollment. The study complied with the principles of the Declaration of Helsinki and international safety guidelines. Patients were divided into two groups: fast and slow progressors according to the monthly reduction in the ALS Functional Rating Scale (ALSFRS-R) from the onset of symptoms to the day of evaluation.</p><p>The ALS Functional Rating Scale-Revised (ALSFRS-R) is a validated 48-point scale measuring physical function in ALS across four domains: bulbar, fine motor, gross motor, and respiratory. Each item is scored from 0 (worst) to 4 (normal), with a maximum score of 48 indicating full function. We used this scale to calculate a Progression Index (PI), which is defined as: PI&#x0202f;=&#x0202f;(48 - ALSFRS-R at diagnosis) / months from symptom onset to diagnosis. Patients with PI &#x02264; 0.5 were defined as slow progressors; those with PI &#x0003e; 0.5 were considered fast progressors (<xref rid="ref20" ref-type="bibr">20</xref>).</p><p>For each patient, we concurrently recorded the latency and amplitude of the compound muscle action potential (CMAP) and the force produced at the level of the flexor digitorum profundus muscle, which stimulates supra-maximally the median nerve at the elbow.</p><p>This study used a Micromed Myoquick 1,400 EMG machine (Micromed S.p. A., Treviso, Italy). CMAP was recorded using surface electrodes (15&#x0202f;&#x000d7;&#x0202f;20&#x0202f;mm, model DENIS15026, Neuro Dart, Spes Medica, Genoa, Italy). The active electrode was placed on the flexor digitorum profundus muscle belly in the forearm, whereas the reference electrode was placed 10&#x0202f;cm distally, in an electrically neutral region.</p><p>Film Pressure Sensor RP-L-110 Resistive film, configured as a closed Wheatstone bridge, was used to detect and quantify human touch pressure. It is a robust polymer thick film (PTF) device that exhibits a decrease in resistance with increasing force applied to the sensor surface. The device was affixed to another rigid surface, and participants were instructed to place their fingers on this surface to register the touch pressure, as shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>. Peak force was defined as the maximum force generated after the supramaximal stimulation of the median nerve at the elbow.</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>The device: the patient&#x02019;s hand is placed on a rigid surface while the fingers touch the sensor.</p></caption><graphic xlink:href="fneur-16-1590950-g001" position="float"/></fig><p>We delivered a single square stimulus with a duration of 200&#x0202f;&#x003bc;s using a constant-current stimulator. The intensity of the stimulus increased steadily until the best response could be obtained. The best motor response had the shortest latency and largest amplitude. Both upper limbs were tested in each participant. For data analysis, we selected the limb with better preserved motor function, as determined by patient history and clinical evaluation, to reduce variability due to asymmetrical progression. We also recorded the creatine kinase (CK) level closest to the day of the visit.</p><p>The IBM SPSS Statistics Data version 26 software was used to analyze the data. The Kruskal&#x02013;Wallis test for independent samples was used to explore group differences. We analyzed the differences between the latency and amplitude of the CMAP and between the amplitude and area of the force developed between the two groups. Mann&#x02013;Whitney U test for independent samples was used to explore the differences in CK values between the groups. The significance level was set at <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05.</p></sec><sec sec-type="results" id="sec9"><title>Results</title><p>According to the revised El Escorial criteria, a total of 44 patients with a definitive diagnosis of amyotrophic lateral sclerosis (ALS) were enrolled in this study. These patients were subsequently stratified into two groups based on their progression index (PI). The first group consisted of 22 patients (10 males and 12 females), among whom 17 presented with spinal-onset ALS, while the remaining 5 exhibited bulbar-onset ALS. These individuals had a PI of &#x02264;0.5 and were classified as slow progressors. The second group also included 22 patients (12 males and 10 females), with an identical distribution of ALS onset types (17 spinal-onset and 5 bulbar-onset). However, these individuals had a PI greater than 0.5 and were categorized as fast progressors.</p><p>In assessing the electrophysiological characteristics of the compound muscle action potential (CMAP), no statistically significant differences were observed between the two groups. The mean CMAP latency was 2.54&#x0202f;&#x000b1;&#x0202f;0.55&#x0202f;ms in the fast progressor group, compared to 2.43&#x0202f;&#x000b1;&#x0202f;0.45&#x0202f;ms in the slow progressor group. Similarly, the mean amplitude of the CMAP did not show a substantial variation, with fast progressors exhibiting an amplitude of 10.45&#x0202f;&#x000b1;&#x0202f;4.45&#x0202f;mV, while slow progressors demonstrated an amplitude of 9.49&#x0202f;&#x000b1;&#x0202f;4.78&#x0202f;mV. These findings suggest that CMAP characteristics alone may not be sufficient to distinguish between fast and slow disease progression in ALS patients.</p><p>However, significant differences were detected in measures of muscle strength and force generation. The amplitude of the peak force was markedly higher in slow progressors (10.5&#x0202f;&#x000b1;&#x0202f;5.7 Newtons [N]) compared to fast progressors (6.3&#x0202f;&#x000b1;&#x0202f;5.1&#x0202f;N), with a statistically significant <italic>p</italic>-value of 0.005. Additionally, the area under the curve (AUC) of force production demonstrated a significant discrepancy between the two groups. Slow progressors exhibited an AUC of 6,465&#x0202f;&#x000b1;&#x0202f;5,300&#x0202f;mV/ms, whereas fast progressors had a considerably lower value of 3,600&#x0202f;&#x000b1;&#x0202f;3,475&#x0202f;mV/ms (<italic>p</italic>&#x0202f;=&#x0202f;0.017). These findings suggest that muscle strength and endurance, as quantified by peak force and AUC, are strongly correlated with disease progression rate in ALS.</p><p>Notably, the creatine kinase (CK) levels between the two groups were different. Indeed, CK values were significantly higher in slow progressors (367.3&#x0202f;&#x000b1;&#x0202f;277.76&#x0202f;U/L) compared to fast progressors (188.2&#x0202f;&#x000b1;&#x0202f;110.49&#x0202f;U/L), with an extremely significant <italic>p</italic>-value of less than 0.001. This suggests that CK levels may serve as a potential biomarker for disease progression, with elevated CK values being more commonly associated with a slower rate of decline in ALS patients.</p><p>A comprehensive summary of these results, including all measured variables, is presented in <xref rid="tab1" ref-type="table">Table 1</xref>. Altogether, these data highlight some key physiological differences between slow and fast progressors, which may offer valuable insights into disease mechanisms and potential therapeutic targets. The observed distinctions in muscle strength, endurance, and CK levels warrant further investigation to explore their potential role in disease monitoring and prognosis.</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Characteristics of the cMAP latency and amplitude, recorded force and CK values of ALS patients, divided into fast and slow progressors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">FAST progressors</th><th align="center" valign="top" rowspan="1" colspan="1">SLOW progressors</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="4" rowspan="1">cMAP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Latency (ms)</td><td align="center" valign="top" rowspan="1" colspan="1">2.542&#x0202f;&#x000b1;&#x0202f;0.552</td><td align="center" valign="top" rowspan="1" colspan="1">2.426&#x0202f;&#x000b1;&#x0202f;0.448</td><td align="center" valign="top" rowspan="1" colspan="1">0.858</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amplitude (mV)</td><td align="center" valign="top" rowspan="1" colspan="1">10.45&#x0202f;&#x000b1;&#x0202f;4.449</td><td align="center" valign="top" rowspan="1" colspan="1">9.488&#x0202f;&#x000b1;&#x0202f;4.778</td><td align="center" valign="top" rowspan="1" colspan="1">0.656</td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">FORCE</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Area (mV/ms)</td><td align="center" valign="top" rowspan="1" colspan="1">3,600&#x0202f;&#x000b1;&#x0202f;3,475</td><td align="center" valign="top" rowspan="1" colspan="1">6,465&#x0202f;&#x000b1;&#x0202f;5,300</td><td align="center" valign="top" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak force amplitude (N)</td><td align="center" valign="top" rowspan="1" colspan="1">6.3&#x0202f;&#x000b1;&#x0202f;5.1</td><td align="center" valign="top" rowspan="1" colspan="1">10.5&#x0202f;&#x000b1;&#x0202f;5.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CK</td><td align="center" valign="top" rowspan="1" colspan="1">188.2&#x0202f;&#x000b1;&#x0202f;110.49</td><td align="center" valign="top" rowspan="1" colspan="1">367.3&#x0202f;&#x000b1;&#x0202f;277.76</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>All data are expressed as mean &#x000b1; SD.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec10"><title>Discussion</title><p>The pathogenesis of ALS remains unclear, and there are currently two main hypotheses regarding its spread: the dying forward and dying back theories (<xref rid="ref21" ref-type="bibr">21</xref>). More recent discoveries have highlighted evidence that pathological changes may begin at the level of the nerve terminal or at the neuromuscular junction (NMJ) and then progress upwards, according to the dying back model (<xref rid="ref22" ref-type="bibr">22</xref>). Muscle tissue has also emerged as a significant factor in ALS, both in its onset and as a potential therapeutic target (<xref rid="ref11" ref-type="bibr">11</xref>).</p><p>In this study, we focused on slow progressors, that are ALS patients who exhibit a low monthly reduction in the ALSFRS-R score. Interestingly, these patients demonstrated ability to develop greater muscle strength despite having the same CMAP values as their faster progressing counterparts (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="fig2"><label>Figure 2</label><caption><p>At the top is the recording of the cMAP, and at the bottom is the recording of the force. The first image belongs to a slow progressor patient, while the second one to a fast progressor. Both recordings were obtained from the supramaximal stimulation of the median nerve at the elbow.</p></caption><graphic xlink:href="fneur-16-1590950-g002" position="float"/></fig><p>Muscle contraction is a complex phenomenon that occurs when the action potential propagates along the MNs and reaches the NMJ, resulting in the release of acetylcholine in the synaptic cleft. The binding of acetylcholine to the nicotinic receptor can induce the propagation of an action potential along the sarcolemma with the consequent release of calcium and the electromechanical coupling of the actin and myosin filaments responsible for muscle contraction. Muscular strength development is influenced by factors such as MN firing rate, motor units number and type, and muscle size (<xref rid="ref23" ref-type="bibr">23</xref>). There are several distinct muscle fibers within muscle tissue that are characterized by different isoform of myosin heavy chain (MyHC) and metabolic activity. Specifically, in human there is one type of slow-twitch fiber (type I) and two types of fast-twitch fibers (type IIa and IIx/d) (<xref rid="ref24" ref-type="bibr">24</xref>). Feeback et al. (<xref rid="ref25" ref-type="bibr">25</xref>) reported that the energy for contraction of Type-I (slow-twitch) fibers was mainly supplied by phosphocreatine shuttle, while in Type-II (fast-twitch) fibers was supplied via energy supply pathway due to glycolytic metabolism. In the two types of single muscle fibers, the CK isoenzymes may play different roles in intracellular energy metabolism. It has been reported that fast-twitch fibers have a higher concentration of phosphocreatine than slow-twitch fibers (<xref rid="ref26" ref-type="bibr">26</xref>). These muscle fibers are sensitive to several factors that cause muscle atrophy and degeneration.</p><p>In ALS, muscle atrophy occurs early together with the dismantling of the NMJ (<xref rid="ref27" ref-type="bibr">27</xref>). The degeneration of MNs in ALS is not homogeneous since different vulnerabilities were observed in different cells. The first cells undergoing degeneration are those that innervate fast-twitch muscle fibers. Slow-twitch muscle fibers are more resistant to degenerative phenomena and, at least in the initial stages, can compensate for the loss of other fibers with a collateral reinnervation (<xref rid="ref28" ref-type="bibr">28</xref>). Nevertheless, this mechanism is not effective as compared with the degenerative process typical of ALS. Notably, enlargement of the motor unit potential and twitch force (<xref rid="ref29" ref-type="bibr">29</xref>) was observed, but it is still not clear whether these reorganized motor units have the same characteristics as normal motor units or as those formed in other reinnervation processes. An increase of motor-unit twitch force has been reported in chronically denervated muscles (<xref rid="ref30" ref-type="bibr">30</xref>) but not in all ALS patients (<xref rid="ref31" ref-type="bibr">31</xref>). The MN sprouting and the resulting increase of twitch force can compensate for the loss of MNs in the early stages of ALS (<xref rid="ref24" ref-type="bibr">24</xref>). Slow-twitch fibers can sustain muscle force for long time, although they are not capable of generating considerable force as it happens with fast twitch fibers (<xref rid="ref24" ref-type="bibr">24</xref>).</p><p>The NMJs innervated by fast-fatigable MNs degenerate rapidly, followed by fast-fatigue-resistant MNs and, finally by slow MNs (<xref rid="ref32" ref-type="bibr">32</xref>). The number of motor units declines in parallel with muscular strength, and the muscle fibers in the remaining motor units, undergo hypertrophy as a compensatory mechanism.</p><p>In this study, an increased force was predominantly found in patients whose disease progression was slightly slower. The corresponding CMAP values were similar among the groups, indicating that the collateral axonal sprouting process played a role in the compensatory mechanism. The CMAP can serve as a surrogate measure of the number of functional motor units because it reflects denervation and reinnervation processes (<xref rid="ref33" ref-type="bibr">33</xref>). However, in a rapidly evolving disease, such as ALS, in which reinnervation is not entirely effective, the amplitude of CMAP tends to decrease over time (<xref rid="ref34" ref-type="bibr">34</xref>). However, the CMAP amplitude can be used roughly to assess disease progression although its accuracy may be compromised by reinnervation (<xref rid="ref35" ref-type="bibr">35</xref>).</p><p>We identified a notable disparity in the peak force amplitude between slow and fast progressors, with slow progressors exhibiting a higher peak. In addition, there was a significant difference in the area under the curve (AUC) for muscle contraction, with slow progressors exhibiting a higher AUC. These findings suggest that slow progressors can maintain a superior muscle function, as evidenced by the elevated peak force and AUC. The peak force reflects the maximum muscle strength that a muscle can exert during contraction, whereas the AUC represents the total power output during muscle contraction. Measuring peak force in ALS can help to evaluate muscle strength preservation or decline due to motor neuron degeneration that leads to muscle weakness and atrophy. Therefore, the elevated values of peak force for slow progressors suggest a better preserved muscle function capable of sustained contraction. Additionally, a higher AUC indicates that the muscle can generate strong contractions and sustain them over the time, which is essential for muscle endurance. In ALS patients, this implies not only strong muscles but also a sustained function, which is potentially associated with slower disease progression. This may contribute to a slower progression of muscle weakness and atrophy.</p><p>In fast progressors, the pronounced degeneration of fast-twitching fibers, despite the reinnervation of slow-twitching fibers, leads to a lower muscle force and CK levels. As these fibers degenerate, the muscle&#x02019;s ability to produce force is diminished, thereby affecting the overall muscle function and strength. Indeed, the slow-twitching fibers, even when reinnervated, cannot fully compensate for the loss of fast-twitching fibers in terms of the force output and maintaining high CK levels (<xref rid="ref36" ref-type="bibr">36</xref>, <xref rid="ref37" ref-type="bibr">37</xref>). Mechanisms such as the activation of specific signaling pathways (e.g., FoxO1-related pathways) (<xref rid="ref36" ref-type="bibr">36</xref>) predominantly affect fast-twitch fibers, leading to their selective atrophy. On the other hand, slow progressors exhibit less degeneration of fast-twitching fibers, which allows them to maintain higher muscle force and CK levels. This could be due to a greater resistance of fast-twitching fibers to degeneration or more effective compensatory mechanisms that preserve muscle integrity (<xref rid="ref38" ref-type="bibr">38</xref>). The difference in creatine kinase (CK) production in fast-twitch muscles could be attributed to the greater force generated by these muscles. Fast-twitch muscles, which are known for producing more force and are associated with rapid and powerful muscle contractions, might require higher CK activity to support rapid energy replenishment during intense exercise (<xref rid="ref39" ref-type="bibr">39</xref>). Muscle-specific creatine kinase (CK-M) is crucial for the reversible transfer of high-energy phosphate from creatine phosphate (CrP) to ADP, a process vital for rapid ATP regeneration during intense muscle activity (<xref rid="ref40" ref-type="bibr">40</xref>). Therefore, increased CK-M activity in fast-twitch muscles may be linked to their efficient energy-generation capacity during intense muscle contractions.</p><p>In addition, there is a weaker electromechanical coupling in ALS patients compared with controls, particularly affecting the fast-contracting motor units. Prolonged fasciculation electromechanical latency in ALS muscles indicates an impairment in the excitation-contraction coupling mechanism, which contributes to muscle weakness (<xref rid="ref13" ref-type="bibr">13</xref>). We identified novel biomarkers of disease progression to further understand the mechanisms underlying muscle dysfunction in ALS. Furthermore, differences in the electromechanical coupling and synchronous firing of motor units in ALS patients and healthy individuals underline the complexity of ALS pathophysiology. A weaker electromechanical coupling, particularly in fast-contracting motor units, highlights the role of muscle function and its alterations in disease progression (<xref rid="ref8" ref-type="bibr">8</xref>).</p><p>Growing evidence suggest that other non-nerve cells, such as glial cells (<xref rid="ref41" ref-type="bibr">41</xref>) and muscle cells (<xref rid="ref42" ref-type="bibr">42</xref>), can contribute to the damage or preservation of MNs. In a previous study it was shown that in animal models and in humans with a better muscle metabolic reserve expressed by elevated CK values, disease progression was much slower (<xref rid="ref28" ref-type="bibr">28</xref>). Higher CK levels in slow progressors might indicate a greater muscle mass or enhanced muscle integrity, potentially associated with a slower disease progression rate. Because of its heterogeneity, ALS presents distinctive phenotypes, including onset pattern, predominance of upper or lower MN involvement, and disease progression rate, which remain poorly understood. These different characteristics suggest the presence of different underlying molecular processes. However, a clear correlation between neuropathological phenomena and different phenotypes is not yet evident. Our findings deepen the understanding of the variability observed in ALS progression and underline the importance of assessing other physiological parameters rather than conventional electrophysiological measures. Identification of distinct muscle force profiles and elevated CK levels in slow progressors may serve as potential biomarkers for predicting disease progression and assessing treatment effectiveness. Notably, it has been suggested that muscle-specific factors, as SIRT1 overexpression, can affect the fiber type composition and potentially improving the pathophysiology of muscle-related conditions. In fact, SIRT1 promotes a shift toward slow-twitch fibers, potentially affecting disease progression and muscle function (<xref rid="ref43" ref-type="bibr">43</xref>).</p><p>It is important to acknowledge several limitations of the study that may impact the interpretation of the results. Firstly, the sample size was relatively small, which may limit the generalizability of the findings. Secondly, the cross-sectional study design precludes the establishment of causal relationships between the observed parameters and disease progression. Further longitudinal studies with larger participant groups are needed to confirm these findings and explore additional factors influencing ALS progression. Unfortunately, respiratory function data (e.g., FVC or SNIP values) were not available for all participants at the time of evaluation and were thus excluded from this analysis. Future studies should aim to integrate these data to further explore their relationship with muscle function and disease progression this study also opens potential implications for rehabilitation strategies. The preservation of muscle strength in slow progressors suggests that early targeted rehabilitation programs aimed at maintaining muscle integrity could be particularly beneficial in this subgroup. Functional exercise and neuromuscular stimulation might help delay functional decline.</p></sec><sec sec-type="conclusions" id="sec11"><title>Conclusion</title><p>The significant differences in peak force and AUC in slow and fast progressors suggest that slow progressors retain a better muscle function. Higher CK values in slow progressors may reflect greater muscle mass or integrity, potentially contributing to slower ALS progression in these patients. These findings could provide new insights into the pathogenesis of ALS, predict the disease progression, and develop new targeted therapies aimed at preserving muscle function.</p></sec></body><back><fn-group><title>Abbreviations</title><fn fn-type="abbr"><p>ALS, Amyotrophic Lateral Sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CMAP, compound muscle action potential; CK, creatine kinase.; AUC, area under the curve; PI, progression index; MUAPs, motor-unit action potentials; MN, motoneuron; NMJ, neuromuscular junction.</p></fn></fn-group><sec sec-type="data-availability" id="sec12"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="sec13"><title>Ethics statement</title><p>The studies involving humans were approved by Comitato etico territoriale Lazio area 1. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec14"><title>Author contributions</title><p>LL: Writing &#x02013; review &#x00026; editing. CC: Writing &#x02013; review &#x00026; editing. MC: Writing &#x02013; review &#x00026; editing. FM: Writing &#x02013; review &#x00026; editing. MD: Writing &#x02013; review &#x00026; editing. EP: Writing &#x02013; review &#x00026; editing. MI: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec16"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec17"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec18"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>RH</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name></person-group>. <article-title>Amyotrophic lateral sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>377</volume>:<fpage>162</fpage>&#x02013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra1603471</pub-id>, PMID: <pub-id pub-id-type="pmid">28700839</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardiman</surname><given-names>O</given-names></name><name><surname>al-Chalabi</surname><given-names>A</given-names></name><name><surname>Chio</surname><given-names>A</given-names></name><name><surname>Corr</surname><given-names>EM</given-names></name><name><surname>Logroscino</surname><given-names>G</given-names></name><name><surname>Robberecht</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Amyotrophic lateral sclerosis</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2017</year>) <volume>3</volume>:<fpage>17071</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2017.71</pub-id>, PMID: <pub-id pub-id-type="pmid">28980624</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoxhaj</surname><given-names>P</given-names></name><name><surname>Hastings</surname><given-names>N</given-names></name><name><surname>Kachhadia</surname><given-names>MP</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Sindhu</surname><given-names>U</given-names></name><name><surname>Durve</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Exploring advancements in the treatment of amyotrophic lateral sclerosis: a comprehensive review of current modalities and future prospects</article-title>. <source>Cureus</source>. (<year>2023</year>) <volume>15</volume>:<fpage>e45489</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.45489</pub-id>, PMID: <pub-id pub-id-type="pmid">37868386</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>L</given-names></name></person-group>. <article-title>Updates on disease mechanisms and therapeutics for amyotrophic lateral sclerosis</article-title>. <source>Cells</source>. (<year>2024</year>) <volume>13</volume>:<fpage>888</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells13110888</pub-id>, PMID: <pub-id pub-id-type="pmid">38891021</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Borg</surname><given-names>J</given-names></name><name><surname>Spooren</surname><given-names>W</given-names></name><name><surname>Caroni</surname><given-names>P</given-names></name></person-group>. <article-title>Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases</article-title>. <source>J Neurosci</source>. (<year>2000</year>) <volume>20</volume>:<fpage>2534</fpage>&#x02013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-07-02534.2000</pub-id>, PMID: <pub-id pub-id-type="pmid">10729333</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muddasir Qureshi</surname><given-names>M</given-names></name><name><surname>Hayden</surname><given-names>D</given-names></name><name><surname>Urbinelli</surname><given-names>L</given-names></name><name><surname>Ferrante</surname><given-names>K</given-names></name><name><surname>Newhall</surname><given-names>K</given-names></name><name><surname>Myers</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS)</article-title>. <source>Amyotroph Lateral Scler</source>. (<year>2006</year>) <volume>7</volume>:<fpage>173</fpage>&#x02013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14660820600640596</pub-id>, PMID: <pub-id pub-id-type="pmid">16963407</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westeneng</surname><given-names>HJ</given-names></name><name><surname>Debray</surname><given-names>TPA</given-names></name><name><surname>Visser</surname><given-names>AE</given-names></name><name><surname>van Eijk</surname><given-names>RPA</given-names></name><name><surname>Rooney</surname><given-names>JPK</given-names></name><name><surname>Calvo</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model</article-title>. <source>Lancet Neurol</source>. (<year>2018</year>) <volume>17</volume>:<fpage>423</fpage>&#x02013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30089-9</pub-id>, PMID: <pub-id pub-id-type="pmid">29598923</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmied</surname><given-names>A</given-names></name><name><surname>Pouget</surname><given-names>J</given-names></name><name><surname>Vedel</surname><given-names>JP</given-names></name></person-group>. <article-title>Electromechanical coupling and synchronous firing of single wrist extensor motor units in sporadic amyotrophic lateral sclerosis</article-title>. <source>Clin Neurophysiol</source>. (<year>1999</year>) <volume>110</volume>:<fpage>960</fpage>&#x02013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1388-2457(99)00032-2</pub-id>, PMID: <pub-id pub-id-type="pmid">10400212</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>F</given-names></name><name><surname>Fujimura</surname><given-names>C</given-names></name><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Furutama</surname><given-names>D</given-names></name><name><surname>Uehara</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS</article-title>. <source>Neurology</source>. (<year>2006</year>) <volume>66</volume>:<fpage>265</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000194316.91908.8a</pub-id>, PMID: <pub-id pub-id-type="pmid">16434671</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>NC</given-names></name><name><surname>Oskarsson</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>LW</given-names></name></person-group>. <article-title>Muscle biopsy evaluation in neuromuscular disorders</article-title>. <source>Phys Med Rehabil Clin N Am</source>. (<year>2012</year>) <volume>23</volume>:<fpage>609</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pmr.2012.06.006</pub-id>, PMID: <pub-id pub-id-type="pmid">22938878</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scaricamazza</surname><given-names>S</given-names></name><name><surname>Salvatori</surname><given-names>I</given-names></name><name><surname>Ferri</surname><given-names>A</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name></person-group>. <article-title>Skeletal muscle in ALS: an unappreciated therapeutic opportunity?</article-title>
<source>Cells</source>. (<year>2021</year>) <volume>10</volume>:<fpage>525</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10030525</pub-id>, PMID: <pub-id pub-id-type="pmid">33801336</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inghilleri</surname><given-names>M</given-names></name><name><surname>Iacovelli</surname><given-names>E</given-names></name></person-group>. <article-title>Clinical neurophysiology in ALS</article-title>. <source>Arch Ital Biol</source>. (<year>2011</year>) <volume>149</volume>:<fpage>57</fpage>&#x02013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.4449/aib.v149i1.1264</pub-id>, PMID: <pub-id pub-id-type="pmid">21412716</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planinc</surname><given-names>D</given-names></name><name><surname>Muhamood</surname><given-names>N</given-names></name><name><surname>Cabassi</surname><given-names>C</given-names></name><name><surname>Iniesta</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Hodson-Tole</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Fasciculation electromechanical latency is prolonged in amyotrophic lateral sclerosis</article-title>. <source>Clin Neurophysiol</source>. (<year>2023</year>) <volume>145</volume>:<fpage>71</fpage>&#x02013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinph.2022.11.005</pub-id>, PMID: <pub-id pub-id-type="pmid">36442378</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vucic</surname><given-names>S</given-names></name><name><surname>Higashihara</surname><given-names>M</given-names></name><name><surname>Sobue</surname><given-names>G</given-names></name><name><surname>Atsuta</surname><given-names>N</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>ALS is a multistep process in south Korean, Japanese, and Australian patients</article-title>. <source>Neurology</source>. (<year>2020</year>) <volume>94</volume>:<fpage>e1657</fpage>&#x02013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000009015</pub-id>, PMID: <pub-id pub-id-type="pmid">32071166</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>E</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Significant CMAP decrement by repetitive nerve stimulation is more frequent in median than ulnar nerves of patients with amyotrophic lateral sclerosis</article-title>. <source>Muscle Nerve</source>. (<year>2012</year>) <volume>45</volume>:<fpage>426</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.22301</pub-id>, PMID: <pub-id pub-id-type="pmid">22334178</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maathuis</surname><given-names>EM</given-names></name><name><surname>Drenthen</surname><given-names>J</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name><name><surname>Visser</surname><given-names>GH</given-names></name><name><surname>Blok</surname><given-names>JH</given-names></name></person-group>. <article-title>The CMAP scan as a tool to monitor disease progression in ALS and PMA</article-title>. <source>Amyotroph Lateral Scler Frontotemporal Degener</source>. (<year>2013</year>) <volume>14</volume>:<fpage>217</fpage>&#x02013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.3109/21678421.2012.732079</pub-id>, PMID: <pub-id pub-id-type="pmid">23134509</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>S</given-names></name><name><surname>Shefner</surname><given-names>JM</given-names></name><name><surname>Logigian</surname><given-names>EL</given-names></name></person-group>. <article-title>Does muscle reinnervation produce electromechanical dissociation in amyotrophic lateral sclerosis?</article-title>
<source>Muscle Nerve</source>. (<year>1995</year>) <volume>18</volume>:<fpage>1335</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.880181119</pub-id>, PMID: <pub-id pub-id-type="pmid">7565934</pub-id>
</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>KR</given-names></name><name><surname>Miller</surname><given-names>RG</given-names></name></person-group>. <article-title>Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis</article-title>. <source>Muscle Nerve</source>. (<year>1996</year>) <volume>19</volume>:<fpage>1391</fpage>&#x02013;<lpage>400</lpage>. doi: <pub-id pub-id-type="doi">10.1002/(SICI)1097-4598(199611)19:11&#x0003c;1391::AID-MUS3&#x0003e;3.0.CO;2-7</pub-id>, PMID: <pub-id pub-id-type="pmid">8874396</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Miller</surname><given-names>RG</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Munsat</surname><given-names>TL</given-names></name></person-group>. <article-title>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</article-title>. <source>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disord</source>. (<year>2000</year>) <volume>1</volume>:<fpage>293</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1080/146608200300079536</pub-id>, PMID: <pub-id pub-id-type="pmid">11464847</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>PH</given-names></name><name><surname>Cheung</surname><given-names>YK</given-names></name></person-group>. <article-title>Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS</article-title>. <source>Neurology</source>. (<year>2006</year>) <volume>67</volume>:<fpage>1314</fpage>&#x02013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000243812.25517.87</pub-id>, PMID: <pub-id pub-id-type="pmid">17030785</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>A</given-names></name></person-group>. <article-title>The dying forward hypothesis of ALS: tracing its history</article-title>. <source>Brain Sci</source>. (<year>2021</year>) <volume>11</volume>:<fpage>300</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci11030300</pub-id>, PMID: <pub-id pub-id-type="pmid">33673524</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiernan</surname><given-names>MC</given-names></name><name><surname>Vucic</surname><given-names>S</given-names></name><name><surname>Cheah</surname><given-names>BC</given-names></name><name><surname>Turner</surname><given-names>MR</given-names></name><name><surname>Eisen</surname><given-names>A</given-names></name><name><surname>Hardiman</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Amyotrophic lateral sclerosis</article-title>. <source>Lancet (London, England)</source>. (<year>2011</year>) <volume>377</volume>:<fpage>942</fpage>&#x02013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(10)61156-7</pub-id>, PMID: <pub-id pub-id-type="pmid">21296405</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trezise</surname><given-names>J</given-names></name><name><surname>Collier</surname><given-names>N</given-names></name><name><surname>Blazevich</surname><given-names>AJ</given-names></name></person-group>. <article-title>Anatomical and neuromuscular variables strongly predict maximum knee extension torque in healthy men</article-title>. <source>Eur J Appl Physiol</source>. (<year>2016</year>) <volume>116</volume>:<fpage>1159</fpage>&#x02013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00421-016-3352-8</pub-id>, PMID: <pub-id pub-id-type="pmid">27076217</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Reggiani</surname><given-names>C</given-names></name></person-group>. <article-title>Fiber types in mammalian skeletal muscles</article-title>. <source>Physiol Rev</source>. (<year>2011</year>) <volume>91</volume>:<fpage>1447</fpage>&#x02013;<lpage>531</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00031.2010</pub-id>, PMID: <pub-id pub-id-type="pmid">22013216</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feeback</surname><given-names>DL</given-names></name><name><surname>Locklear</surname><given-names>I</given-names></name><name><surname>Brumback</surname><given-names>RA</given-names></name></person-group>. <article-title>Metabolic myopathy produced by dinitrofluorobenzene inhibition of creatine phosphokinase</article-title>. <source>J Neurol Sci</source>. (<year>1988</year>) <volume>88</volume>:<fpage>219</fpage>&#x02013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-510X(88)90219-5</pub-id>, PMID: <pub-id pub-id-type="pmid">3225621</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesch</surname><given-names>PA</given-names></name><name><surname>Thorsson</surname><given-names>A</given-names></name><name><surname>Fujitsuka</surname><given-names>N</given-names></name></person-group>. <article-title>Creatine phosphate in fiber types of skeletal muscle before and after exhaustive exercise</article-title>. <source>J Appl Physiol</source>. (<year>1985</year>) <volume>66</volume>:<fpage>1756</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1152/jappl.1989.66.4.1756</pub-id>, PMID: <pub-id pub-id-type="pmid">2732167</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>KJ</given-names></name><name><surname>Cheung</surname><given-names>CJ</given-names></name><name><surname>Restrepo</surname><given-names>CR</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Stieber</surname><given-names>AM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group>. <article-title>Selective motor neuron resistance and recovery in a new inducible mouse model of TDP-43 Proteinopathy</article-title>. <source>J Neurosci</source>. (<year>2016</year>) <volume>36</volume>:<fpage>7707</fpage>&#x02013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1457-16.2016</pub-id>, PMID: <pub-id pub-id-type="pmid">27445147</pub-id>
</mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccanti</surname><given-names>M</given-names></name><name><surname>Pozzilli</surname><given-names>V</given-names></name><name><surname>Cambieri</surname><given-names>C</given-names></name><name><surname>Libonati</surname><given-names>L</given-names></name><name><surname>Onesti</surname><given-names>E</given-names></name><name><surname>Frasca</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Creatine kinase and progression rate in amyotrophic lateral sclerosis</article-title>. <source>Cells</source>. (<year>2020</year>) <volume>9</volume>:<fpage>1174</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells9051174</pub-id>, PMID: <pub-id pub-id-type="pmid">32397320</pub-id>
</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>T</given-names></name><name><surname>Nix</surname><given-names>WA</given-names></name></person-group>. <article-title>Functional properties of motor units in motor neuron diseases and neuropathies</article-title>. <source>Electroencephalogr Clin Neurophysiol</source>. (<year>1997</year>) <volume>105</volume>:<fpage>328</fpage>&#x02013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0924-980X(97)00028-3</pub-id>, PMID: <pub-id pub-id-type="pmid">9284241</pub-id>
</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McComas</surname><given-names>AJ</given-names></name><name><surname>Sica</surname><given-names>REP</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name><name><surname>Upton</surname><given-names>ARM</given-names></name></person-group>. <article-title>Functional compensation in partially denervated muscles</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>1971</year>) <volume>34</volume>:<fpage>453</fpage>&#x02013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.34.4.453</pub-id>, PMID: <pub-id pub-id-type="pmid">4938133</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dengler</surname><given-names>R</given-names></name><name><surname>Konstanzer</surname><given-names>A</given-names></name><name><surname>Hesse</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>W</given-names></name></person-group>. <article-title>Collateral nerve sprouting and twitch forces of single motor units in conditions with partial denervation in man</article-title>. <source>Neurosci Lett</source>. (<year>1989</year>) <volume>97</volume>:<fpage>118</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0304-3940(89)90149-3</pub-id>, PMID: <pub-id pub-id-type="pmid">2918993</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pun</surname><given-names>S</given-names></name><name><surname>Santos</surname><given-names>AF</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Caroni</surname><given-names>P</given-names></name></person-group>. <article-title>Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF</article-title>. <source>Nat Neurosci</source>. (<year>2006</year>) <volume>9</volume>:<fpage>408</fpage>&#x02013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nn1653</pub-id>, PMID: <pub-id pub-id-type="pmid">16474388</pub-id>
</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dengler</surname><given-names>R</given-names></name></person-group>. <article-title>Quantitative compound muscle action potential: con</article-title>. <source>Amyotroph Lateral Scler Other Motor Neuron Disord</source>. (<year>2002</year>) <volume>3</volume>:<fpage>S105</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1080/146608202320374462</pub-id>, PMID: <pub-id pub-id-type="pmid">12396825</pub-id>
</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Ballantyne</surname><given-names>JP</given-names></name></person-group>. <article-title>A quantitative electrophysiological study of motor neurone disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>1978</year>) <volume>41</volume>:<fpage>773</fpage>&#x02013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.41.9.773</pub-id>, PMID: <pub-id pub-id-type="pmid">690647</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><name><surname>Thibodeau</surname><given-names>L</given-names></name><name><surname>Andres</surname><given-names>PL</given-names></name><name><surname>Finison</surname><given-names>LJ</given-names></name></person-group>. <article-title>Use of electrophysiologic tests to measure disease progression in ALS therapeutic trials</article-title>. <source>Muscle Nerve</source>. (<year>1990</year>) <volume>13</volume>:<fpage>471</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.880130602</pub-id>, PMID: <pub-id pub-id-type="pmid">2195338</pub-id>
</mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pessin</surname><given-names>JE</given-names></name></person-group>. <article-title>Mechanisms for fiber-type specificity of skeletal muscle atrophy</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. (<year>2013</year>) <volume>16</volume>:<fpage>243</fpage>&#x02013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MCO.0b013e328360272d</pub-id>, PMID: <pub-id pub-id-type="pmid">23493017</pub-id>
</mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venoj&#x000e4;rvi</surname><given-names>M</given-names></name><name><surname>Kvist</surname><given-names>M</given-names></name><name><surname>Atalay</surname><given-names>M</given-names></name><name><surname>Jozsa</surname><given-names>L</given-names></name><name><surname>Kalimo</surname><given-names>H</given-names></name></person-group>. <article-title>Recovery from immobilisation: responses of fast-twitch muscle fibres to spontaneous and intensive exercise in rat calf muscles</article-title>. <source>Pathophysiology</source>. (<year>2004</year>) <volume>11</volume>:<fpage>17</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pathophys.2003.10.002</pub-id>, PMID: <pub-id pub-id-type="pmid">15177511</pub-id>
</mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosoi</surname><given-names>T</given-names></name><name><surname>Yakabe</surname><given-names>M</given-names></name><name><surname>Sasakawa</surname><given-names>H</given-names></name><name><surname>Sasako</surname><given-names>T</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Sarcopenia phenotype and impaired muscle function in male mice with fast-twitch muscle-specific knockout of the androgen receptor</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2023</year>) <volume>120</volume>:<fpage>e2218032120</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2218032120</pub-id>, PMID: <pub-id pub-id-type="pmid">36669097</pub-id>
</mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watchko</surname><given-names>JF</given-names></name><name><surname>Daood</surname><given-names>MJ</given-names></name><name><surname>LaBella</surname><given-names>JJ</given-names></name></person-group>. <article-title>Creatine kinase activity in rat skeletal muscle relates to myosin phenotype during development</article-title>. <source>Pediatr Res</source>. (<year>1996</year>) <volume>40</volume>:<fpage>53</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1203/00006450-199607000-00010</pub-id>, PMID: <pub-id pub-id-type="pmid">8798246</pub-id>
</mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echegaray</surname><given-names>M</given-names></name><name><surname>Rivera</surname><given-names>MA</given-names></name></person-group>. <article-title>Role of creatine kinase isoenzymes on muscular and cardiorespiratory endurance: genetic and molecular evidence</article-title>. <source>Sports Med</source>. (<year>2001</year>) <volume>31</volume>:<fpage>919</fpage>&#x02013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.2165/00007256-200131130-00003</pub-id>, PMID: <pub-id pub-id-type="pmid">11708401</pub-id>
</mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraiuolo</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>K</given-names></name><name><surname>Sherwood</surname><given-names>TW</given-names></name><name><surname>Vick</surname><given-names>J</given-names></name><name><surname>Likhite</surname><given-names>S</given-names></name><name><surname>Frakes</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2016</year>) <volume>113</volume>:<fpage>E6496</fpage>&#x02013;<lpage>505</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1607496113</pub-id>, PMID: <pub-id pub-id-type="pmid">27688759</pub-id>
</mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepore</surname><given-names>E</given-names></name><name><surname>Casola</surname><given-names>I</given-names></name><name><surname>Dobrowolny</surname><given-names>G</given-names></name><name><surname>Musar&#x000f2;</surname><given-names>A</given-names></name></person-group>. <article-title>Neuromuscular junction as an entity of nerve-muscle communication</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>8</volume>:<fpage>906</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells8080906</pub-id>, PMID: <pub-id pub-id-type="pmid">31426366</pub-id>
</mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalkiadaki</surname><given-names>A</given-names></name><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Nasamu</surname><given-names>AS</given-names></name><name><surname>Knezevic</surname><given-names>J</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name></person-group>. <article-title>Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of duchenne muscular dystrophy</article-title>. <source>PLoS Genet</source>. (<year>2014</year>) <volume>10</volume>:<fpage>e1004490</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1004490</pub-id>, PMID: <pub-id pub-id-type="pmid">25032964</pub-id>
</mixed-citation></ref></ref-list></back></article>